Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Sees Large Increase in Short Interest

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 2,300 shares, an increase of 360.0% from the March 31st total of 500 shares. Based on an average trading volume of 4,600 shares, the days-to-cover ratio is currently 0.5 days.

Inhibitor Therapeutics Price Performance

Inhibitor Therapeutics stock remained flat at $0.09 during trading hours on Friday. The stock has a market cap of $14.76 million, a P/E ratio of -8.58 and a beta of -0.84. The business’s fifty day simple moving average is $0.07 and its 200 day simple moving average is $0.08. Inhibitor Therapeutics has a one year low of $0.01 and a one year high of $0.30.

Inhibitor Therapeutics (OTCMKTS:INTI) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.01) earnings per share for the quarter.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.